









市场行情
/
股票
/
nasdaq-dnli
/

Denali Therapeutics Inc

DNLI

16.510USD

+0.100+0.61%

收盘 12/31, 16:00（美东）报价延迟15分钟

2.42B总市值

亏损市盈率 TTM



Denali Therapeutics Inc

16.510

+0.100+0.61%

概览公司财务分析

概览

公司

财务

分析

关于 Denali Therapeutics Inc 公司

Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.

Denali Therapeutics Inc简介



公司代码DNLI

公司名称Denali Therapeutics Inc

上市日期Dec 08, 2017

CEOWatts (Ryan J)

员工数量422

证券类型Ordinary Share

年结日Dec 08

公司地址161 Oyster Point Blvd.

城市SOUTH SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94080

电话16508668547

网址https://www.denalitherapeutics.com

公司代码DNLI

上市日期Dec 08, 2017

CEOWatts (Ryan J)

Denali Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Ryan J. Watts, Ph.D.

President, Chief Executive Officer, Director

2.46M

Dr. Alexander O. Schuth, M.D.

Chief Operating and Financial Officer, Secretary

765.12K

-0.38%

Mr. Jay T. Flatley

Independent Director

352.53K

+1.74%

Dr. David P. Schenkein, M.D.

Independent Director

72.72K

+9.05%

Mr. Peter S. Klein

Independent Director

27.53K

+28.08%

Ms. Jennifer E. Cook

Independent Director

26.07K

+30.13%

Dr. Marc Tessier-Lavignec, Ph.D.

Independent Director

Mr. Steven E. (Steve) Krognes

Director

Ms. Nancy A. Thornberry

Independent Director

Mr. Julian C. Baker

Independent Chairman of the Board

名称

名称/职务

职务

持股

持股变动

Dr. Ryan J. Watts, Ph.D.

President, Chief Executive Officer, Director

2.46M

Dr. Alexander O. Schuth, M.D.

Chief Operating and Financial Officer, Secretary

765.12K

-0.38%

Mr. Jay T. Flatley

Independent Director

352.53K

+1.74%

Dr. David P. Schenkein, M.D.

Independent Director

72.72K

+9.05%

Mr. Peter S. Klein

Independent Director

27.53K

+28.08%

Ms. Jennifer E. Cook

Independent Director

26.07K

+30.13%

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月30日周日

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

7.68%

Baillie Gifford & Co.

7.44%

BlackRock Institutional Trust Company, N.A.

6.50%

Biogen Inc

4.59%

T. Rowe Price Investment Management, Inc.

3.62%

其他

70.17%

持股股东

占比

The Vanguard Group, Inc.

7.68%

Baillie Gifford & Co.

7.44%

BlackRock Institutional Trust Company, N.A.

6.50%

Biogen Inc

4.59%

T. Rowe Price Investment Management, Inc.

3.62%

其他

70.17%

股东类型

持股股东

占比

Investment Advisor

50.30%

Investment Advisor/Hedge Fund

18.27%

Hedge Fund

13.58%

Sovereign Wealth Fund

5.97%

Individual Investor

4.64%

Corporation

4.59%

Research Firm

2.24%

Bank and Trust

1.01%

Private Equity

0.64%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

523

144.23M

92.59%

-5.13M

2025Q3

534

148.30M

106.07%

+2.76M

2025Q2

533

144.90M

104.92%

+4.11M

2025Q1

521

140.91M

100.82%

-5.51M

2024Q4

508

135.26M

104.03%

-2.70M

2024Q3

500

139.34M

103.43%

+2.39M

2024Q2

486

129.82M

93.98%

+2.48M

2024Q1

475

127.09M

84.98%

+6.07M

2023Q4

485

116.85M

84.85%

+2.16M

2023Q3

479

114.98M

85.46%

+1.16M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

11.96M

7.68%

+173.41K

+1.47%

Sep 30, 2025

Baillie Gifford & Co.

11.59M

7.44%

-363.74K

-3.04%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

10.13M

6.5%

+257.90K

+2.61%

Sep 30, 2025

Biogen Inc

7.16M

4.59%

-5.60M

-43.89%

Oct 30, 2024

T. Rowe Price Investment Management, Inc.

5.64M

3.62%

+2.39M

+73.66%

Sep 30, 2025

State Street Investment Management (US)

5.46M

3.51%

+946.27K

+20.94%

Sep 30, 2025

Temasek Holdings Pte. Ltd.

5.36M

3.44%

Sep 30, 2025

Fidelity Management & Research Company LLC

5.01M

3.22%

-2.40M

-32.37%

Sep 30, 2025

Capital Research Global Investors

4.76M

3.06%

+10.28K

+0.22%

Sep 30, 2025

T. Rowe Price Associates, Inc.

4.43M

2.85%

-2.03M

-31.37%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Neuroscience and Healthcare ETF

4.13%

Global X Guru Index ETF

1.33%

ALPS Medical Breakthroughs ETF

0.98%

Virtus LifeSci Biotech Clinical Trials ETF

0.74%

State Street SPDR S&P Biotech ETF

0.73%

Direxion Daily S&P Biotech Bull 3X Shares

0.45%

Global X Aging Population ETF

0.38%

ProShares Ultra Nasdaq Biotechnology

0.35%

iShares Health Innovation Active ETF

0.35%

Invesco Nasdaq Biotechnology ETF

0.23%

iShares Neuroscience and Healthcare ETF

占比4.13%

Global X Guru Index ETF

占比1.33%

ALPS Medical Breakthroughs ETF

占比0.98%

Virtus LifeSci Biotech Clinical Trials ETF

占比0.74%

State Street SPDR S&P Biotech ETF

占比0.73%

Direxion Daily S&P Biotech Bull 3X Shares

占比0.45%

Global X Aging Population ETF

占比0.38%

ProShares Ultra Nasdaq Biotechnology

占比0.35%

iShares Health Innovation Active ETF

占比0.35%

Invesco Nasdaq Biotechnology ETF

占比0.23%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Denali Therapeutics Inc的前五大股东是谁？



Denali Therapeutics Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：11.96M，占总股份比例：7.68%。
Baillie Gifford & Co.持有股份：11.59M，占总股份比例：7.44%。
BlackRock Institutional Trust Company, N.A.持有股份：10.13M，占总股份比例：6.50%。
Biogen Inc持有股份：7.16M，占总股份比例：4.59%。
T. Rowe Price Investment Management, Inc.持有股份：5.64M，占总股份比例：3.62%。